|
1
|
Dolecek TA, Propp JM, Stroup NE and
Kruchko C: CBTRUS statistical report: Primary brain and central
nervous system tumors diagnosed in the United States in 2005–2009.
Neuro Oncol. 14 (Suppl 5):v1–v49. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Alexander BM and Cloughesy TF: Adult
glioblastoma. J Clin Oncol. 35:2402–2409. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Jovčevska I, Kočevar N and Komel R: Glioma
and glioblastoma-how much do we (not) know? Mol Clin Oncol.
1:935–941. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Moreno M, Pedrosa L, Paré L, Pineda E,
Bejarano L, Martínez J, Balasubramaniyan V, Ezhilarasan R,
Kallarackal N, Kim SH, et al: GPR56/ADGRG1 inhibits mesenchymal
differentiation and radioresistance in glioblastoma. Cell Rep.
21:2183–2197. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chen Q, Cai J, Wang Q, Wang Y, Liu M, Yang
J, Zhou J, Kang C, Li M and Jiang C: Long non-coding RNA NEAT1,
regulated by the EGFR pathway, contributes to glioblastoma
progression through the WNT/β-Catenin pathway by scaffolding EZH2.
Clin Cancer Res. 24:684–695. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wang W, Zhao Z, Wu F, Wang H, Wang J, Lan
Q and Zhao J: Bioinformatic analysis of gene expression and
methylation regulation in glioblastoma. J Neurooncol. 136:495–503.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Malumbres M: Cyclin-dependent kinases.
Genome Biol. 15:1222014. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Malumbres M and Barbacid M: Cell cycle,
CDKs and cancer: A changing paradigm. Nat Rev Cancer. 9:153–166.
2009. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Xi Q, Huang M, Wang Y, Zhong J, Liu R, Xu
G, Jiang L, Wang J, Fang Z and Yang S: The expression of CDK1 is
associated with proliferation and can be a prognostic factor in
epithelial ovarian cancer. Tumour Biol. 36:4939–4948. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sung WW, Lin YM, Wu PR, Yen HH, Lai HW, Su
TC, Huang RH, Wen CK, Chen CY, Chen CJ and Yeh KT: High
nuclear/cytoplasmic ratio of Cdk1 expression predicts poor
prognosis in colorectal cancer patients. BMC Cancer. 14:9512014.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kim SJ, Nakayama S, Miyoshi Y, Taguchi T,
Tamaki Y, Matsushima T, Torikoshi Y, Tanaka S, Yoshida T, Ishihara
H and Noguchi S: Determination of the specific activity of CDK1 and
CDK2 as a novel prognostic indicator for early breast cancer. Ann
Oncol. 19:68–72. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Griesinger AM, Birks DK, Donson AM, Amani
V, Hoffman LM, Waziri A, Wang M, Handler MH and Foreman NK:
Characterization of distinct immunophenotypes across pediatric
brain tumor types. J Immunol. 191:4880–4888. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang X, Kang DD, Shen K, Song C, Lu S,
Chang LC, Liao SG, Huo Z, Tang S, Ding Y, et al: An R package suite
for microarray meta-analysis in quality control, differentially
expressed gene analysis and pathway enrichment detection.
Bioinformatics. 28:2534–2536. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ritchie ME, Phipson B, Wu D, Hu Y, Law CW,
Shi W and Smyth GK: Limma powers differential expression analyses
for RNA-sequencing and microarray studies. Nucleic Acids Res.
43:e472015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gene Ontology Consortium: Gene Ontology
Consortium: Going forward. Nucleic Acids Res. 43:D1049–D1056. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Majewska E and Szeliga M: AKT/GSK3β
signaling in glioblastoma. Neurochem Res. 42:918–924. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chen Q and Li W, Wan Y, Xia X, Wu Q, Chen
Y, Lai Z, Yu C and Li W: Amplified in breast cancer 1 enhances
human cholangiocarcinoma growth and chemoresistance by simultaneous
activation of Akt and Nrf2 pathways. Hepatology. 55:1820–1829.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Dolma S, Selvadurai HJ, Lan X, Lee L,
Kushida M, Voisin V, Whetstone H, So M, Aviv T, Park N, et al:
Inhibition of dopamine receptor D4 impedes autophagic flux,
proliferation, and survival of glioblastoma stem cells. Cancer
Cell. 29:859–873. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Rapp C, Warta R, Stamova S, Nowrouzi A,
Geisenberger C, Gal Z, Roesch S, Dettling S, Juenger S, Bucur M, et
al: Identification of T cell target antigens in glioblastoma
stem-like cells using an integrated proteomics-based approach in
patient specimens. Acta Neuropathol. 134:297–316. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Shapiro GI: Cyclin-dependent kinase
pathways as targets for cancer treatment. J Clin Oncol.
24:1770–1783. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chen X, Zhang FH, Chen QE, Wang YY, Wang
YL, He JC and Zhou J: The clinical significance of CDK1 expression
in oral squamous cell carcinoma. Med Oral Patol Oral Cir Bucal.
20:e7–e12. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhang C, Elkahloun AG, Robertson M, Gills
JJ, Tsurutani J, Shih JH, Fukuoka J, Hollander MC, Harris CC,
Travis WD, et al: Loss of cytoplasmic CDK1 predicts poor survival
in human lung cancer and confers chemotherapeutic resistance. PloS
One. 6:e238492011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Tsaur I, Makarević J, Hudak L, Juengel E,
Kurosch M, Wiesner C, Bartsch G, Harder S, Haferkamp A and Blaheta
RA: The cdk1-cyclin B complex is involved in everolimus triggered
resistance in the PC3 prostate cancer cell line. Cancer Lett.
313:84–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Willder JM, Heng SJ, McCall P, Adams CE,
Tannahill C, Fyffe G, Seywright M, Horgan PG, Leung HY, Underwood
MA and Edwards J: Androgen receptor phosphorylation at serine 515
by Cdk1 predicts biochemical relapse in prostate cancer patients.
Br J Cancer. 108:139–148. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zeestraten EC, Maak M, Shibayama M,
Schuster T, Nitsche U, Matsushima T, Nakayama S, Gohda K, Friess H,
van de Velde CJ, et al: Specific activity of cyclin-dependent
kinase I is a new potential predictor of tumour recurrence in stage
II colon cancer. Br J Cancer. 106:133–140. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hers I, Vincent EE and Tavare JM: Akt
signalling in health and disease. Cell Signal. 23:1515–1527. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Martini M, De Santis MC, Braccini L,
Gulluni F and Hirsch E: PI3K/AKT signaling pathway and cancer: An
updated review. Ann Med. 46:372–383. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Guo D, Reinitz F, Youssef M, Hong C,
Nathanson D, Akhavan D, Kuga D, Amzajerdi AN, Soto H, Zhu S, et al:
An LXR agonist promotes glioblastoma cell death through inhibition
of an EGFR/AKT/SREBP-1/LDLR-dependent pathway. Cancer Discov.
1:442–456. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Li X, Wu C, Chen N, Gu H, Yen A, Cao L,
Wang E and Wang L: PI3K/Akt/mTOR signaling pathway and targeted
therapy for glioblastoma. Oncotarget. 7:33440–33450.
2016.PubMed/NCBI
|
|
30
|
Manning BD and Cantley LC: AKT/PKB
signaling: Navigating downstream. Cell. 129:1261–1274. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Pestell RG, Albanese C, Reutens AT, Segall
JE, Lee RJ and Arnold A: The cyclins and cyclin-dependent kinase
inhibitors in hormonal regulation of proliferation and
differentiation. Endocr Rev. 20:501–534. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Warfel NA, Dolloff NG, Dicker DT, Malysz J
and El-Deiry WS: CDK1 stabilizes HIF-α via direct phosphorylation
of Ser668 to promote tumor growth. Cell Cycle. 12:3689–3701.
View Article : Google Scholar : PubMed/NCBI
|
